

The State of Al in Commercial Products

Tico Blumenthal Vice President of Product, Eko Health


Heartland Workshop on Heart Sounds and Al June 2023




Access, Cost and Quality are critical objectives

INEQUITABLE ACCESS

This map shows where social vulnerability and poor access to healthcare in the United States intersect. Massive gaps persist in the South and among rural, urban and tribal communities, which illustrate shortcomings of the industry to provide care to people that need it most.



Source: Modern Healthcare analysis of Centers for Disease Control and Prevention and the Health Resources and Services Administration data



care (curative care; rehabilitative care, long-term care, anciliary services, and medical goods) and collective services (prevention and public health services as well as health administration), but excluding spending on investments. Shown is total health expenditure (financed by public and private sources).

OurWorldinData.org - Research and data to make progress against the world's largest problems.



Clinically-facing AI offers opportunities, rapid growth



Hospitals report 10-15+ Al companies calling *per week*



Source: Beckers Hospital Review, May 16th, 2024, Iink

38% of physicians report using AI¹, many see success, some barriers

The pace of innovation is accelerating


eko eko

Eko's founding insight

Over 1 billion stethoscope exams per year

Every day, cardiopulmonary disease is going undetected on the front-lines of care.

.. because they're using outdated tools.






By helping clinicians hear better, and listen confidently

we earn their trust to help them find disease earlier, when better care is most impactful

The Eko Health Platform







© 2023 Eko Health, Inc. *EHR integration/SSO optional



500,000+ Eko devices in clinician hands

Largest installed base of Al-enabled point-of-care devices, globally




A growth story

Eko collected the largest dataset of heart sounds and lung sounds for Al development.


Better auscultation and more insights have become a reality for millions of patients every week.


Quicker answers, and solutions, for higher quality care.



SENSORATM

Cardiac Disease Detection







Our Key Markets: HF and VHD

Over 423,000 people die from HF and VHD each year...¹

15M+

patients in the US have Valvular Heart Disease² or Heart Failure¹

\$80 billion

annual US cost for treating HF and VHD patients1

...and detection before presentation to the emergency room remains a challenge, leaving many untreated.

every 10 min

someone dies in the US from HF or Valvular Heart Disease³

3. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2017 on CDC WONDER Online Database, released December, 2018. Data are from the Multiple Cause of Death Files, 1999-2017, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/ucd-icd10.html on Oct 24, 2019.

Martin et Al (2024). 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. JCirculation 2024;149:e347–e913

Otto CM, Bonow RO. Valvular Heart Disease: A Companion to Braunwald's Heart Disease. 4th ed. Philadelphia, PA: Elsevier Saunders; 2014.
 2023 Eko Health, Inc.

Roughly 40% of HF is discovered in acute care

Accurate and timely detection is key to ensuring the best patient care and outcomes

Detection

Auscultate: Murmur identification and characterization

Diagnosis

Diagnose: Confirm with echocardiogram

Treatment

Treat: Medical Management, Intervention










SENSORA™ Platform

What's included?











Arrhythmia Detection

FDA 510k cleared in Nov 2019

Detects:

- Atrial Fibrillation
- Bradycardia/Tachycardia
- "Other" Arrhythmia
- Normal Sinus Rhythm






15-second Recordings, across 1 or multiple points


Murmur Characterization

FDA 510k cleared in June 2022


Detects:

- Structural Systolic Murmurs
- Structural Diastolic Murmurs







Murmur Characterization



SENSORA™ Al more than doubles detection accuracy vs. PCPs





¹ Gardezi, Syed Khurram Mushtaq, et al. Cardiac auscultation in diagnosing valvular heart disease: a comparison between general practitioners and cardiologists. European Heart Journal, Vol. 38 (2017): 1155



² Siliste RN, Siliste C. Physical examination in aortic valve disease: do we still need it in the modern era? European Society of Cardiology, Vol. 18 (2020), N° 12

³ Eko Murmur Analysis Software User Manual, LBL 295 Rev B. Structural murmur identification in adult patients (>18 years old)).FDA submission data.

⁴ Data on file. Announcing at AHA

Reduced Ejection Fraction


FDA 510k cleared in March 2024

Detects:

Individuals with Ejection fraction < 40%



Lancet Digital Health 2022



Reduced Ejection Fraction

FDA Test Set

Leveraging ECG & Heart Sounds


Prospective study on 3,456 unique individuals

Ground truth confirmed by echocardiogram

10% prevalence of Reduced EF

Sensitivity = 74.7%

Specificity = 77.5%



American Heart Association 2023



A Randomized Controlled Trial of 1,195 women between the ages of 18 and 49 were enrolled in the study and completed necessary baseline tests. About 73% were pregnant at the beginning of the study; and 39% were in their third trimester.

Results

Al-guided screening (digital stethoscope maximum prediction across all locations recorded) doubled cardiomyopathy detection (4.1%)compared to the control arm (1.8%).

Al showed an impressive AUC of 0.98, 100.0% sensitivity, and 79.4% specificity, underscoring its significant potential to assist in the detection and appropriate management of cardiomyopathy in pregnant women.

Community Partnerships

HeartSense



Antoine Keller, MD, FACC, FACS - 1st
Co-founder of HeartSense | Cardiothoracic Surgeon at Ochsner Lafayette ...
1d - (5)

Being part of our community's events and well-being is imperative in shifting the heart health equity and access paradigm. This weekend HeartSense had the opportunity to participate in the Love Heals Free Clinics event at the Raising Cane's River Center - ASM Global. Using the Eko Health SENSORA™ platform, we detected ten structural murmurs - Of those, six individuals had no prior knowledge of their condition nor access to a cardiologist.

Thank you to our HeartSense volunteers and staff and Cody Hitchcock for training on the SENSORA™ platform to further enhance our heart screening capabilities.

If you want to partner with HeartSense to bring heart screening to your community, please get in touch with info@heart-sense.org.


#hearthealth #healthequity #healthcareonlinkedin #ekohealth







The insight and skills of a specialist, in the hands of physicians and patients, to deliver care everywhere.

This is the future of healthcare.







Indications for Use

CORE

Indications for Use: The Eko CORE is an electronic stethoscope that enables amplification, filtering, and transmission of auscultation sound data (heart, lungs, bowel, arteries, and veins), whereby a clinician at one location on network can listen to the auscultation sounds of a patient on site or at a different location on the network. Eko CORE is intended for use on pediatric and adult patients. The Eko CORE is intended to be used by professional users in a clinical environment or by lay users in a nonclinical environment. The device is not intended for self-diagnosis.

DUO

Indications for Use: The Eko DUO System is intended to be used by healthcare professionals to electronically amplify, filter, and transfer body sounds and single-channel electrocardiogram (ECG) waveforms. The Eko DUO System also displays ECG waveforms and phonocardiogram waveforms on the accompanying mobile application for storage and sharing (when prescribed or used under the care of a physician). It can be used to record heart sounds and cardiac murmurs, bruits, respiratory sounds, and abdominal sounds during physical examination in normal patients or those with suspected diseases of the cardiac, vascular, pulmonary, or abdominal organ systems. The device can be used on adults and pediatrics.

The data offered by the device is only significant when used in conjunction with physician over read as well as consideration of other relevant patient data.

The device should not be used on infants weighing less than 10kg.

Eko Murmur Analysis Software

The Eko Murmur Analysis Software is intended to provide decision support to clinicians in their evaluation of patients' heart sounds. The software analyzes heart sounds and phonocardiograms (and ECG signals, when available). The software will automatically detect murmurs that may be present, and the murmur timing and character, including S1, S2, innocent heart murmurs, structural heart murmurs, and the absence of a heart murmur.

The Eko Murmur Analysis Software is not intended as a sole means of diagnosis and is for use in environments where healthcare is provided by clinicians. The interpretations of heart sounds offered by the software are meant only to provide decision support to the clinician, who may use the result in conjunction with their own evaluation and clinical judgment. The interpretations are not diagnoses. The Eko Murmur Analysis Software is intended for use on pediatric and adult patients.



